Patient-oriented choice of therapy for inflammatory bowel diseases: a clinical case

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The presented clinical case demonstrates the difficulties in choosing biological therapy for induction and maintenance of remission of Crohn’s disease (CD) and the need for a patient-oriented approach taking into account the patient’s profile and clinical situation. TOne of the effective drugs with a high safety profile, including elderly patients, low immunogenicity, which remains effective in the 2nd and further line of biological therapy, is an anti-cytokine drug, a monoclonal antibody against the p40 subunits of IL-12 and IL-23 ustekinumab.

Full Text

Restricted Access

About the authors

I. G. Bakulin

North-Western State Medical University named after I.I. Mechnikov

Email: Mariya.Zhuravleva@szgmu.ru
ORCID iD: 0000-0002-6151-2021

Dr. Sci. (Med.), Professor, Head of the Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietetics named after S.M. Ryss

Russian Federation, St. Petersburg

Maria S. Zhuravleva

North-Western State Medical University named after I.I. Mechnikov

Author for correspondence.
Email: Mariya.Zhuravleva@szgmu.ru
ORCID iD: 0000-0003-4838-5707

Cand. Sci. (Med.), Associate Professor, Associate Professor at the Department of Propaedeutics of Internal Medicine, Gastroenterology and Dietetics named after S.M. Ryss

Russian Federation, St. Petersburg

M. M. Bereznitskaya

North-Western State Medical University named after I.I. Mechnikov

Email: Mariya.Zhuravleva@szgmu.ru
ORCID iD: 0009-0007-1407-1378

Resident in the specialty «Gastroenterology», Department of Propaedeutics of Internal Diseases, Gastroenterology and Dietetics named after S.M. Ryss

Russian Federation, St. Petersburg

E. V. Gutman

Leningrad Regional Clinical Hospital

Email: Mariya.Zhuravleva@szgmu.ru
ORCID iD: 0009-0007-3025-2195

Head of the Gastroenterology Department

Russian Federation, St. Petersburg

T. A. Egorova

Leningrad Regional Clinical Hospital

Email: Mariya.Zhuravleva@szgmu.ru
ORCID iD: 0009-0001-4114-4882

Gastroenterologist, Gastroenterology Department

Russian Federation, St. Petersburg

References

  1. Шелыгин Ю.А., Ивашкин В.Т., Ачкасов С.И. и др. Болезнь Крона (К50), взрослые. Колопроктология. 2023;22(3):10–49. [Shelygin Yu.A., Ivashkin V.T., Achkasov S.I. et al. Crohn’s disease (K50), adults. Coloproctology. 2023;22(3):10–49. (In Russ.)]. doi: 10.33878/2073-7556-2023-22-3-10-49.
  2. Шелыгин Ю.А., Ивашкин В.Т., Белоусова Е.А. и др. Язвенный колит (К51), взрослые. Колопроктология. 2023;22(1):10–44. [Shelygin Yu.A., Ivashkin V.T., Belousova E.A. et al. Ulcerative colitis (K51), adults. Coloproctology. 2023;22(1):10–44. (In Russ.)]. doi: 10.33878/2073-7556-2023-22-1-10-44.
  3. Белоусова Е.А., Шелыгин Ю.А., Ачкасов С.И. и др. Клинико-демографические характеристики и лечебные подходы у пациентов с воспалительными заболеваниями кишечника (болезнь Крона, язвенный колит) в РФ. Первые результаты анализа Национального регистра. Колопроктология. 2023;22(1):65–82. [Belousova E.A., Shelygin Yu.A., Achkasov. S.I., et al. Clinical and demographic characteristics and treatment approaches in patients with inflammatory bowel diseases (Crohn’s disease, ulcerative colitis) in the Russian Federation. First results of the National Registry analysis. Coloproctology. 2023;22(1):65–82. (In Russ.)]. doi: 10.33878/2073-7556-2023-22-1-65-82.
  4. Imbrizi M., Magro F., Coy C.S.R. Pharmacological therapy in inflammatory bowel diseases: a narrative review of the past 90 years. Pharmaceuticals. 2023;16(9):1272. doi: 10.3390/ph16091272.
  5. Zurba Y., Gros B., Shehab M. Exploring the pipeline of novel therapies for inflammatory bowel disease; state of the art review. Biomedicines. 2023;11:747. doi: 10.3390/biomedicines11030747.
  6. Hanauer S.B., Feagan B.G., Lichtenstein G.R. et al. Maintenance infliximab for Crohn’s disease: The ACCENT I randomised trial. Lancet. 2002;359(9317):1541–1549. doi: 10.1016/S0140-6736(02)08512-4.
  7. Sands B.E., Anderson F.H., Bernstein C.N. et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350(9):876–885. doi: 10.1056/NEJMoa030815.
  8. Sandborn W.J., Feagan B.G., Rutgeerts, P. et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369(8):711–721. doi: 10.1056/NEJMoa1215739.
  9. Feagan B.G., Sandborn W.J., Gasink C. et al.; UNITI–IM-UNITI Study Group. Ustekinumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2016;375(20):1946–1960. doi: 10.1056/NEJMoa1602773.
  10. Loftus E.V., Panes J., Lacerda A.P. et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–1980. doi: 10.1056/NEJMoa2212728.
  11. Danese S., Solitano V., Jairath V., Peyrin-Biroulet L. The future of drug development for inflammatory bowel disease: the need to ACT (advanced combination treatment). Gut. 2022;71(12):2380–2387. doi: 10.1136/gutjnl-2022-327025.
  12. Бакулин И.Г., Скалинская М.И., Маев И.В. и др. Фармакотерапия воспалительных заболеваний кишечника: управление эффективностью и безопасностью. Терапевтический архив. 2021;93(8):841–852. [Bakulin I.G., Skalinskaya M.I., Maev I.V., et al. Pharmacotherapy of inflammatory bowel diseases: management of efficacy and safety. Therapeutic archive. 2021;93(8):841–852. (In Russ.)]. doi: 10.26442/00403660.2021.08.200982.
  13. Бакулин И.Г., Жигалова Т.Н., Латария Э.Л. и др. Опыт внедрения Федерального регистра пациентов с воспалительными заболеваниями кишечника в Санкт-Петербурге. Фарматека. 2017;S5:56–59. [Bakulin I.G., Zhigalova T.N., Latariya E.L., et al. Experience of implementing the Federal Register of patients with inflammatory bowel diseases in St. Petersburg. Farmateka. 2017;S5:56–59. (In Russ.)].
  14. Tontini G.E., Vecchi M., Pastorelli L. et al. Differential diagnosis in inflammatory bowel disease colitis: state of the art and future perspectives. World J Gastroenterol. 2015;21(1):21–46. doi: 10.3748/wjg.v21.i1.21.
  15. Melmed G.Y., Elashoff R., Chen G.C. et al. Predicting a change in diagnosis from ulcerative colitis to Crohn’s disease: a nested, case-control study. Clin Gastroenterol Hepatol. 2007;5(5):602–608; doi: 10.1016/j.cgh.2007.02.015.
  16. Berends S.E., Strik A.S., Löwenberg M. et al. Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis. Clin Pharmacokinet. 2019;58(1):15–37. doi: 10.1007/s40262-018-0676-z.
  17. D’Amico F., Peyrin-Biroulet L., Danese S. Ustekinumab in Crohn’s disease: new data for positioning in treatment algorithm. J Crohns Colitis. 2022;16(Suppl 2):ii30–ii41. doi: 10.1093/ecco-jcc/jjac011.
  18. Белоусова Е.А., Абдулхаков Р.А., Бакулин И.Г. и др. Эффективность и безопасность устекинумаба у пациентов со среднетяжелым и тяжелым активным язвенным колитом в российской популяции: субанализ международного исследования III фазы индукционной и поддерживающей терапии (UNIFI) на протяжении 3 лет. Колопроктология. 2023;22(1):54–64. [Belousova E.A., Abdulkhakov R.A., Bakulin I.G., et al. Efficacy and safety of ustekinumab in patients with moderate to severe active ulcerative colitis in the Russian population: a subanalysis of the international phase III study of induction and maintenance therapy (UNIFI) over 3 years. Coloproctology. 2023;22(1):54–64. (In Russ.)]. doi: 10.33878/2073-7556-2023-22-1-54-64.
  19. Strand V., Balsa A., Al-Saleh J. еt al. Immunogenicity of biologics in chronic inflammatory diseases: a systematic review. BioDrugs. 2017;31(4):299–316. doi: 10.1007/s40259-017-0231-8.
  20. Battat R., Kopylov U., Bessissow T. et al. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients with Crohn’s disease. Clin Gastroenterol Hepatol. 2017;15:1427–34.e2. doi: 10.1016/j.cgh.2017.03.032.
  21. Singh S., Murad M.H., Fumery M. et al. Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn’s disease: a systematic review and network meta-analysis. Lancet Gastroenterol Hepatol. 2021;6(12):1002–1014. doi: 10.1016/S2468-1253(21)00312-5.
  22. Biemans V.B.C., van der Woude C.J., Dijkstra G. et al. Ustekinumab is associated with superior effectiveness outcomes compared with vedolizumab in Crohn’s disease patients with prior failure to anti-TNF treatment. Aliment Pharmacol Ther. 2020;52:123–134. doi: 10.1111/apt.15745.
  23. Garg R., Aggarwal M., Butler R. et al. Real-world effectiveness and safety of ustekinumab in elderly Crohn’s disease patients. Dig Dis Sci. 2022;67(7):3138–3147. doi: 10.1007/s10620-021-07117-9.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Рис. Эндофото колоноскопии (ноябрь 2022 г.) пациента Ш. (предоставлено врачом-эндоскопистом отделения эндоскопии больницы им. Петра Великого Голубевой К.В.) A - сливные эрозии слизистой оболочки нисходящей ободочной кишки, покрытые фибрином; Б - зона стриктуры сигмовидной кишки; В - сливные эрозии, спонтанная кровоточивость слизистой оболочки сигмовидной кишки.

Download (324KB)
Indexing metadata

Copyright (c) 2025 Bionika Media